Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Minimum Information about T Regulatory Cells: A Step toward Reproducibility and Standardization.
Show others and affiliations
2018 (English)In: Frontiers in Immunology, ISSN 1664-3224, E-ISSN 1664-3224, Vol. 8, article id 1844Article in journal (Refereed) Published
Abstract [en]

Cellular therapies with CD4+ T regulatory cells (Tregs) hold promise of efficacious treatment for the variety of autoimmune and allergic diseases as well as posttransplant complications. Nevertheless, current manufacturing of Tregs as a cellular medicinal product varies between different laboratories, which in turn hampers precise comparisons of the results between the studies performed. While the number of clinical trials testing Tregs is already substantial, it seems to be crucial to provide some standardized characteristics of Treg products in order to minimize the problem. We have previously developed reporting guidelines called minimum information about tolerogenic antigen-presenting cells, which allows the comparison between different preparations of tolerance-inducing antigen-presenting cells. Having this experience, here we describe another minimum information about Tregs (MITREG). It is important to note that MITREG does not dictate how investigators should generate or characterize Tregs, but it does require investigators to report their Treg data in a consistent and transparent manner. We hope this will, therefore, be a useful tool facilitating standardized reporting on the manufacturing of Tregs, either for research purposes or for clinical application. This way MITREG might also be an important step toward more standardized and reproducible testing of the Tregs preparations in clinical applications.

Place, publisher, year, edition, pages
2018. Vol. 8, article id 1844
Keywords [en]
T regulatory cells, cell therapy, good manufacturing practice, immune tolerance, immunotherapy, minimum information model
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:uu:diva-342893DOI: 10.3389/fimmu.2017.01844ISI: 000419897500001PubMedID: 29379498OAI: oai:DiVA.org:uu-342893DiVA, id: diva2:1185332
Funder
EU, Horizon 2020Available from: 2018-02-23 Created: 2018-02-23 Last updated: 2018-03-01Bibliographically approved

Open Access in DiVA

fulltext(4629 kB)15 downloads
File information
File name FULLTEXT01.pdfFile size 4629 kBChecksum SHA-512
ae9d99f883b23d9b3a5670c4fdda7c3b6567f5f0a350042a6ddffec10c1f24b71b267aa043097fb7c4e556a0a4027d43c4649f6a2eca5ca913946b678f091b6d
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Berglund, DavidKorsgren, Olle
By organisation
Clinical Immunology
In the same journal
Frontiers in Immunology
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
Total: 15 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 14 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf